Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

Noa Biran, MD, Hackensack Meridian Health
Conference Coverage
Evaluating Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma
05/06/2024

Featuring Noa Biran, MD

Featuring Noa Biran, MD
Noa Biran, MD, evaluates a variety of treatment options for patients with relapsed/refractory multiple myeloma at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Noa Biran, MD, evaluates a variety of treatment options for patients with relapsed/refractory multiple myeloma at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Noa Biran, MD, evaluates a...
05/06/2024
Oncology
Sam Yamshon, MD, Weill Cornell Medicine
Conference Coverage
Safety of CAR T-Cell Therapy Following FDA Warning on Risk of Secondary Malignancies Following Treatment
05/06/2024

Featuring Sam Yamshon, MD

Featuring Sam Yamshon, MD
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the...
05/06/2024
Oncology

Advertisement

Jennifer Amengual, MD, Columbia University
Conference Coverage
Novel Therapeutic Targets for Elderly Patients With Diffuse Large B-Cell Lymphoma
05/06/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jennifer Amengual, MD, discusses novel therapeutic targets for elderly patients with DLBCL who are not candidates for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jennifer Amengual, MD, discusses novel therapeutic targets for elderly patients with DLBCL who are not candidates for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
05/06/2024
Oncology
Balazs Halmos, MD, Montefiore Einstein Comprehensive Cancer Center
Conference Coverage
Exploring Optimal Treatment for Patients With STK-11– and KEAP-1–Mutated Lung Cancer
05/03/2024

Featuring Balazs Halmos, MD

Featuring Balazs Halmos, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Balazs Halmos MD, discussed the addition of CTLA-4 inhibition in the treatment of STK-11– and KEAP-1–mutated lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Balazs Halmos MD, discussed the addition of CTLA-4 inhibition in the treatment of STK-11– and KEAP-1–mutated lung cancer.
At the Great Debates and Updates...
05/03/2024
Oncology
Rebecca Heist, MD, MPH, Massachusetts General Hospital
Conference Coverage
Targeted Therapies for Patients With Lung Cancer Exhibiting BRAF Mutations or MET Skipping Alterations
05/02/2024

Featuring Rebecca Heist, MD, MPH

Featuring Rebecca Heist, MD, MPH ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Rebecca Heist, MD, MPH, debated in favor of using targeted therapy for patients with lung cancer who exhibit BRAF mutations or MET exon 14 skipping alterations.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Rebecca Heist, MD, MPH, debated in favor of using targeted therapy for patients with lung cancer who exhibit BRAF mutations or MET exon 14 skipping alterations.
At the Great Debates and Updates...
05/02/2024
Oncology

Advertisement

Koosha Paydary, MD, MPH, MSc, Rush University Medical Center
Conference Coverage
CTLA-4 Inhibitors for Patients With PD-L1–Negative/PD-L1<1% Lung Cancer
04/29/2024

Featuring Koosha Paydary, MD, MPH, MSc

Featuring Koosha Paydary, MD, MPH, MS...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Koosha Paydary, MD, MPH, MSc, argued that CTLA-4 inhibitors should not be used to treat patients with PD-L1 negative or PD-L1
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Koosha Paydary, MD, MPH, MSc, argued that CTLA-4 inhibitors should not be used to treat patients with PD-L1 negative or PD-L1
At the Great Debates and Updates...
04/29/2024
Oncology
Charles Simone, MD
Conference Coverage
Addition of Stereotactic Body Radiation Therapy to Systemic Therapy Improves Outcomes Among Patients With Oligometastatic, Oligoprogressive NSCLC
04/28/2024

Featuring Charles Simone, MD

Featuring Charles Simone, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that adding SBRT to systemic therapy is a strong and effective way to treat patients with oligometastatic or oligoprogressive non-small...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that adding SBRT to systemic therapy is a strong and effective way to treat patients with oligometastatic or oligoprogressive non-small...
At the Great Debates and Updates...
04/28/2024
Oncology
Jamie Chaft, MD, Memorial Sloan-Kettering Cancer Center
Conference Coverage
The Benefit of Perioperative Immunotherapy in Lung Cancer Treatment
04/28/2024

Featuring Jamie Chaft, MD

Featuring Jamie Chaft, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, argued in favor of both pre- and post-operative immunotherapy in the treatment of lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, argued in favor of both pre- and post-operative immunotherapy in the treatment of lung cancer.
At the Great Debates and Updates...
04/28/2024
Oncology

Advertisement

Charles Simone, MD
Conference Coverage
Non-Surgical Interventions for Patients With Stage 3 Non-Small Cell Lung Cancer
04/27/2024

Featuring Charles Simone, MD

Featuring Charles Simone, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates...
04/27/2024
Oncology
Gareth Morgan, MD, NYU Langone Medical Center
Conference Coverage
Assessing the Strength of Minimal Residual Disease Testing for Patients With Multiple Myeloma
04/19/2024

Featuring Gareth Morgan, MD

Featuring Gareth Morgan, MD
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in...
04/19/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use